Drug Trial Radar · NCT00410982
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Last checked: Nov 20, 2026Latest source record: Jun 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Dec 2006
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 13, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to find the highest tolerated dose of gemcitabine that can be given with busulfan and melphalan. The safety of this drug combination will also be studied.
Conditions
- Leukemia
- Lymphoma
- Myeloma
Interventions
BusulfanDrug
Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous
GemcitabineDrug
Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.
MelphalanDrug
Day -3 and Day -2 = 60 mg/m\^2 Intravenous.
Hematopoietic Cell TransplantationOther
Infusion of stem cells on Day 0.
Rituximab for Patients with B-Cell MalignanciesDrug
375 mg/m\^2 Intravenous on Days 1 and 8.
PaliferminDrug
60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of Gemcitabine with Busulfan + MelphalanTime frame: Baseline to Day 100 post transplant, up to 115 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.